Welcome to our dedicated page for Nexgel Wt Exp 120126 SEC filings (Ticker: NXGLW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating NexGel’s R&D spending on electron-beam cross-linked hydrogels or tracking when executives buy warrants can take hours. The company’s filings are packed with technical terms about transdermal delivery science, FDA clearances, and contract-manufacturing revenue splits—details investors can’t afford to miss. If you have ever typed “NexGel SEC filings explained simply” or “how do I read NexGel’s annual report 10-K?” this page is built for you.
Stock Titan’s AI quickly translates dense disclosures into plain language. Need the NexGel quarterly earnings report 10-Q filing summarized before the market opens? Our engine highlights wound-care segment margins, cash burn, and backlog in seconds. Want alerts on NexGel insider trading Form 4 transactions? We stream NexGel Form 4 insider transactions real-time, flagging option exercises tied to milestone trials. From NexGel executive stock transactions Form 4 to an NexGel 8-K material events explained feed, every document lands here as soon as EDGAR posts it—complete with AI-powered summaries, keyword search, and side-by-side comparisons.
Investors use these insights to:
- monitor FDA-driven catalysts announced in 8-Ks
- compare hydrogel manufacturing costs across quarters
- review the NexGel proxy statement executive compensation for alignment with shareholder returns
- dive into an NexGel annual report 10-K simplified view that links R&D intensity to future growth
- follow NexGel earnings report filing analysis for margin trends
NexGel reported consolidated revenue of $2.884 million for the quarter ended June 30, 2025, up from $1.440 million a year earlier, and $5.690 million for the six months versus $2.706 million in 2024. Growth was driven largely by its consumer branded products, which produced $1.884 million in the quarter (vs. $968 thousand) and $3.666 million for six months (vs. $1.585 million).
Despite revenue gains, NexGel remains unprofitable: net loss attributable to NexGel stockholders was $1.377 million for the six months and the company used $807 thousand in operating cash over the period. Cash on hand was $725 thousand at June 30, 2025 and working capital was about $1.8 million, which the company says raises substantial doubt about its ability to continue as a going concern. Management is pursuing expanded sales channels, product development and possible financing to address liquidity needs.
NexGel, Inc. furnished a press release reporting the Companys results for the quarter ended June 30, 2025, attached as Exhibit 99.1, and disclosed a new investor presentation attached as Exhibit 99.2.
The filing states these materials are being furnished (not "filed") for purposes of the Exchange Act and therefore are not automatically incorporated by reference into other securities filings. The cover information lists the Companys common stock and warrants trading on The Nasdaq Capital Market under the symbols NXGL and NXGLW, and indicates the Company is an emerging growth company.
NexGel director Jerome B. Zeldis received a stock option grant on June 25, 2025 for 30,000 shares of common stock at an exercise price of $2.32 per share. The options were granted under the company's 2019 Long-Term Incentive Plan for board service through the 2026 Annual Meeting.
Key terms of the stock option grant:
- Vesting schedule: Equal monthly installments of 2,500 shares over 12 months starting July 31, 2025
- Expiration date: June 25, 2035
- Exercise price: $2.32 per share
- Accelerated vesting provision in case of Change in Control
This Form 4 filing indicates continued alignment of director compensation with shareholder interests through equity-based incentives. The 10-year exercise period and monthly vesting schedule are typical for director equity compensation plans.